echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > This type of therapy for the primary cause of death of non-alcoholic fatty liver is becoming an emerging research direction

    This type of therapy for the primary cause of death of non-alcoholic fatty liver is becoming an emerging research direction

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Non-alcoholic fatty liver disease (NAFLD) is becoming the most prevalent liver disease in the world.


    Although liver disease caused by NASH is the primary cause of liver transplantation, due to the close connection between NAFLD and type 2 diabetes, most patients with NASH die due to cardiovascular and metabolic diseases rather than liver-related causes


    The strong link between NAFLD and type 2 diabetes

    The strong link between NAFLD and type 2 diabetes

    Existing evidence shows that there is a two-way interaction between NAFLD or NASH and type 2 diabetes


    On the other hand, the accumulation of liver fat is associated with decreased insulin sensitivity.


    We already know that the risk of cardiovascular disease (CVD) and chronic kidney disease in diabetic patients will be significantly increased, and the risk of CVD and chronic kidney disease in NAFLD patients will also increase


    ▲The role of insulin resistance in NAFLD (picture source: reference [1])

    In recent years, some scholars have proposed the use of "metabolic-associated fatty liver disease" (metabolic-associated fatty liver disease) to describe a wider population of fatty liver disease than NAFLD


    Based on the interaction between NAFLD, NASH and type 2 diabetes, targeting insulin sensitivity and hyperglycemia, and adopting a more comprehensive strategy for the treatment of metabolic diseases may bring better treatment results


    The effect of anti-diabetic drugs in the treatment of NAFLD

    The effect of anti-diabetic drugs in the treatment of NAFLD

    At present, a variety of anti-diabetic drugs have been used to treat NAFLD and NASH in preclinical and clinical studies


    ▲The effect of anti-diabetic drugs in the treatment of NAFLD (ALT: alanine aminotransferase; AST: aspartate aminotransferase; DNL: de novo lipogenesis; data source: reference [1], drawing by WuXi AppTec's content team)

    GLP1 modulator

    GLP1 is an endogenous hormone secreted by the intestinal tract.


    In clinical trials, exenatide, liraglutide and semaglutide have shown efficacy in reducing liver lipid levels, liver transaminase and inflammation markers


    Compared with placebo, smeglutide significantly increased the proportion of patients whose symptoms of NASH were eliminated in the phase 2 clinical trial, and did not cause the deterioration of liver fibrosis


    Since the expression level of GLP1 receptors in the liver is very low, the effect of GLP1 modulators on liver endpoints may not be due to a direct effect on the liver, but an overall improvement in the patient's metabolic indicators


    ▲The proportion of other diseases in NAFLD patients (picture source: reference [1])

    Thiazolidinediones

    Thiazolidinedione drugs can stimulate the secretion of adipokines, increase insulin sensitivity, promote the storage of triglycerides in adipose tissue, and inhibit fat lysis, which leads to a decrease in the level of free fatty acids in the blood and lower liver fat.


    In addition, thiazolidinedione drugs can also directly inhibit the activation and fibrosis of hepatic stellate cells in the rat model


    Among the approved thiazolidinediones, pioglitazone has a relatively small ability to activate PPARγ and has relatively few adverse reactions


    ▲Pioglitazone molecular structure (picture source: PubChem)

    SGLT2 inhibitor

    SGLT2 is a sodium-dependent glucose transporter expressed mainly in the kidney, and it is mainly responsible for the reabsorption of glucose


    In clinical trials for the treatment of patients with NAFLD and type 2 diabetes, a variety of SGLT2 inhibitors can reduce blood sugar while improving liver lipid levels, reducing liver transaminase levels and liver stiffness
    .

    Similar to GLP1 modulators, SGLT2 inhibitors can cause weight loss, which is closely related to the decrease in liver lipid levels, and SGLT2 is not expressed in the liver
    .
    Therefore, the improvement in liver lipid levels may be due to weight loss and improved metabolic indicators
    .
    The review authors pointed out that whether SGLT2 inhibitors can improve the histological characteristics of the liver in the treatment of NASH patients still needs to be evaluated by clinical trials
    .

    Conclusion

    Conclusion

    The review authors stated that due to the close connection between NAFLD and type 2 diabetes, many drugs used to treat hyperglycemia have achieved positive results in improving NASH biomarkers
    .
    In addition to hypoglycemic drugs, a variety of research therapies targeting lipid metabolism have also achieved a certain degree of effect
    .
    Taken together, targeted metabolism therapies are attractive in the treatment of NAFLD and NASH because they may reduce the risk of cardiovascular disease and other complications related to type 2 diabetes, which is the primary cause of death in patients with NAFLD and NASH Reason
    .

    Reference materials:

    [1] Ferguson and Finck, (2021).
    Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.
    Nature Reviews Endocrinology, https://doi.
    org/10.
    1038/s41574-021-00507-z

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.